CAR T cells in cancer therapy

View the CAR T cells in cancer therapy poster

December 2017

T cells engineered to express chimeric antigen receptors (CARs) are ‘living drugs’ designed to eliminate cancer cells. CAR T cells targeting CD19, a cell surface molecule expressed in most leukaemias and lymphomas, have shown remarkable results in patients with acute lymphoblastic leukaemia. This poster overviews the different ways to design and produce CAR T cells and the journey that has driven these CAR T cells to FDA approval in 2017.

The Poster is freely available online thanks to support from Lonza Bioscience Solutions.

Lonza – Your Partner in Immunotherapy Research

Lonza is committed to supporting your immunotherapy research by providing primary cells, media and both large- and small-volume transfection solutions to help you transition from research into therapy. If you’re ready for the clinic, our cell therapy services might be the answer you need for development, manufacturing and testing of your cell-based therapeutics.

Cells and Media

Whether you need a mixed population of PBMCs, purified natural killer cells or unprocessed bone marrow for setting up your application, Lonza has the optimal cell and media solution you’re looking for. If you don’t see the cells that you need in our catalog, we can likely isolate them for you through our Cells on Demand Service.

Transfection

Lonza’s Nucleofector™ Technology enables efficient non-viral T cell modification, e.g. for generating CAR T cells. Transfections can now be scaled seamlessly from 100,000 to 1 billion cells using the established 4D-Nucleofector™ System including our latest addition, the Large Volume Unit.

Clinical Cell Therapy Services

We partner with clients to develop client-specific custom protocols to meet each unique business need, from raw material requirements and process flow to storage and distribution.

Please visit www.lonza.com/immunotherapy for additional information or contact scientific.support@lonza.com.